戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 npoint a novel target for development of new antibacterials.
2 O synthase inhibitors, antitumor agents, and antibacterials.
3 class of selective, nontoxic, broad-spectrum antibacterials.
4 achieve with previously reported DNA binding antibacterials.
5 uirement for a major novel scaffold class of antibacterials.
6  as lead compounds in the development of new antibacterials.
7 n inhibitors and prospective targets for new antibacterials.
8 nthesis, and a target of recently discovered antibacterials.
9 em as the specific cellular target for these antibacterials.
10 ated with 0-2 days and 1560 with 5-7 days of antibacterials.
11 outcomes are similar with 0-2 vs 5-7 days of antibacterials.
12  aureus and Streptococcus pneumoniae rely on antibacterials.
13  with positive respiratory virus assays with antibacterials.
14 epresent a large untapped reservoir of novel antibacterials.
15 sis on the total chemical synthesis of novel antibacterials.
16 ess between "innovative" and "noninnovative" antibacterials.
17  and identified from Cystobacter sp as novel antibacterials.
18 on aiming at the discovery of more effective antibacterials.
19 ions, such as neurodegenerative diseases and antibacterials.
20 ustry to take actions in the quest for novel antibacterials.
21 abaceae are promising lead compounds for new antibacterials.
22 nd has the potential to aid discovery of new antibacterials.
23  is not exploited by any clinically approved antibacterials.
24 d be a target for the future design of novel antibacterials.
25 g starting point for further optimization as antibacterials.
26 gulation and potentially for intervention by antibacterials.
27 ide the bacterium is a pivotal step for most antibacterials.
28 ising the utility of the carbapenem class of antibacterials.
29 rious issues of resistance to currently used antibacterials.
30 e synergistic effects of combinations of ASL antibacterials.
31 rs such as fluoroquinolone and aminocoumarin antibacterials.
32  certain quinolones might help develop newer antibacterials.
33 esis, making LpxC a promising target for new antibacterials.
34 arget for the development of highly specific antibacterials.
35 is a suitable target for the design of novel antibacterials.
36 ns of antibacterials or ACSs with or without antibacterials.
37 alidated target for the development of novel antibacterials.
38 olecule and place it in the wider context of antibacterials.
39 efore, represent potential targets for novel antibacterials.
40 cacy of available treatments and develop new antibacterials.
41 s and the target of the sulfonamide class of antibacterials.
42 excellent targets for the development of new antibacterials.
43 s sortase as a target for the development of antibacterials.
44 ng alanine racemase an attractive target for antibacterials.
45 eath, making it an attractive target for new antibacterials.
46 s a renewed interest in the discovery of new antibacterials.
47  associated with lower use of broad-spectrum antibacterials (0.61; .54-.70) and higher narrow-spectru
48 icrobials in 47% of patients, by addition of antibacterials (20%) (mostly against anaerobes [12.7%]),
49                  To address the need for new antibacterials, a number of bacterial genomes have been
50 rm for the development of MraY inhibitors as antibacterials against drug-resistant bacteria.
51 As part of a study to optimize the quinolone antibacterials against M. tuberculosis, we have prepared
52 tential to become a new class of sustainable antibacterials against specific human pathogens.
53 derived from previously reported pyrrolamide antibacterials and a fragment-based approach targeting t
54 o leverage their structures to develop novel antibacterials and chemical probes.
55 ght patients treated with 0-2 vs 5-7 days of antibacterials and compared outcomes overall and for dif
56 l envelope of the bacterium may identify new antibacterials and new adjuvants that preserve the effic
57 l envelope of the bacterium may identify new antibacterials and new adjuvants that preserve the effic
58 ines" includes among indispensable medicines antibacterials and pain and migraine relievers.
59  difficulty of discovering new and effective antibacterials and the rapid development of resistance p
60  in our understanding of the pharmacology of antibacterials and their optimal use in the care of pati
61 , placebo-controlled trial of acyclovir plus antibacterials and were monitored for 28 days.
62 the treatment of PJI, compared with systemic antibacterials, and are not sufficient to support recomm
63 re medical treatment (eg, antiviral therapy, antibacterials, and pain control) occur in up to 40% of
64 uenza alone, when comparing 0 vs 5-7 days of antibacterials, and when restricting to patients with IC
65                            We identified all antibacterials approved and launched in the G7 and 7 oth
66                                 CRISPR-based antibacterials are a novel and adaptable method for buil
67 acterials or spacers with different loads of antibacterials are needed to evaluate the safety and eff
68                                          New antibacterials are needed to tackle antibiotic-resistant
69                                          New antibacterials are needed to treat community-acquired ba
70 monellosis globally, yet Salmonella-specific antibacterials are not available.
71 cture-based strategies for developing topo2A antibacterials are suggested.
72                                        Novel antibacterials are urgently needed to address the growin
73 g is a method to classify target pathways of antibacterials based on how bacteria respond to treatmen
74 es resistance to one of the highly effective antibacterials, beta-lactams.
75 salivary flow, numerous salivary components, antibacterials (both natural and applied), fluoride from
76 is not a class effect of the fluoroquinolone antibacterials but is highly dependent upon specific sub
77        Venturicidins alone are not effective antibacterials but recently were found to have adjuvant
78 beta-Lactams are the most important class of antibacterials, but their use is increasingly compromise
79                   Aminoglycosides are potent antibacterials, but therapy is compromised by substantia
80 very and optimization of this novel class of antibacterials by the use of structure-guided design, mo
81                 The increasing resistance to antibacterials commonly employed in the clinic and the g
82      This approach, using phages as targeted antibacterials, could extend the lifetime of our current
83 ysis demonstrated wide use of broad-spectrum antibacterials, despite a paucity of evidence for bacter
84  oxazolidinones are a new class of synthetic antibacterials effective against a broad range of pathog
85  have evolved resistance to nearly all known antibacterials, emphasizing the need to identify antibio
86   We have created a class of small synthetic antibacterials, exemplified by PC190723, which inhibits
87 DSA), included a recommendation to prescribe antibacterials for CAP upon detection of a respiratory v
88  AU-FQ hybrids are a promising new family of antibacterials for treatment of antibiotic-resistant Gra
89    Administration of certain fluoroquinolone antibacterials has been associated with prolongation of
90         However, developing sphaerimicins as antibacterials has been challenging due to their complex
91                                   A class of antibacterials has been discovered that inhibits the gro
92               The current development of new antibacterials has lagged far behind.
93 ependent discovery of the quinolone class of antibacterials have been almost entirely overlooked by t
94                            Recent studies on antibacterials have focused on the development of antimy
95 er the past forty years, efforts to discover antibacterials have yielded a wide variety of chemical s
96  difficult to imagine life without effective antibacterials; however, the inexorable rise of antibiot
97          Quinolones are the most active oral antibacterials in clinical use and act by increasing DNA
98 , for which we have extended our coverage of antibacterials in partnership with AntibioticDB, a colla
99 n response, we have extended our coverage of antibacterials in partnership with AntibioticDB.
100 e desirable over traditional, broadly acting antibacterials in several contexts.
101   Twenty publications that reported doses of antibacterials in spacers and had a follow-up of >/= 24
102 d studies evaluating the choice and doses of antibacterials in spacers.
103 shed data do not allow evaluation of whether antibacterials in temporary cement spacers provide addit
104 ing yet fascinating, and might lead to novel antibacterials in the future.
105  emphasizing the potential of nitro drugs as antibacterials in various bacterial species.
106 l IIIC and were up to 64-fold more potent as antibacterials in vitro against Gram+ bacteria.
107 rting important roles for these unrecognized antibacterials in vivo.
108        We then discuss inhibition of MurJ by antibacterials, including humimycins and the phage M lys
109                               Broad spectrum antibacterials, including streptomycin, rifampicin, and
110 biotics, an important new class of synthetic antibacterials, inhibit protein synthesis by interfering
111  to antibiotics and the poor pipeline of new antibacterials is creating a major health issue worldwid
112                    A paucity of novel acting antibacterials is in development to treat the rising thr
113                        Patient access to new antibacterials is limited in some high-income countries
114 ades, the repertoire of clinically effective antibacterials is shrinking due to the rapidly increasin
115             The mechanism of the beta-lactam antibacterials is the functionally irreversible acylatio
116 terial penicillins (J01C), other beta-lactam antibacterials (J01D), sulfonamides and trimethoprim (J0
117 es and streptogramins (J01F), aminoglycoside antibacterials (J01G), quinolone antibacterials (J01M),
118 noglycoside antibacterials (J01G), quinolone antibacterials (J01M), combinations of antibacterials (J
119 olone antibacterials (J01M), combinations of antibacterials (J01R) and other antibacterials (J01X).
120 binations of antibacterials (J01R) and other antibacterials (J01X).
121 mulation affect the lethal action of diverse antibacterials, leading to the hypothesis that killing b
122 l and one of the newest clinically important antibacterials, linezolid, inhibit protein synthesis by
123                                              Antibacterials may be initiated out of concern for bacte
124 cetamol, i.e., 4-aminophenol (4-AP), and two antibacterials, namely, cefadroxil (CFD, beta-lactam ant
125 s, antiemetics, gastrointestinal stimulants, antibacterials, narcotics, antipsychotics, inotropes, di
126 n of 22 pharmacologically active substances (antibacterials, nonsteroidal antiinflammatories, antisep
127 rting point for the discovery of many of the antibacterials now in use.
128                     The development of novel antibacterials, optimization of treatment approaches, im
129 either ACSs with different concentrations of antibacterials or ACSs with or without antibacterials.
130 ed trials comparing spacers with and without antibacterials or spacers with different loads of antiba
131 lthcare facility visits (p = 0.05), received antibacterials (p & 0.01) and had > 3 antibacterial cour
132 althcare facility visits (P = .05), received antibacterials (P < .01), and had >3 antibacterial cours
133 olidinones, totally synthetic class of novel antibacterials, possess activity against drug-resistant
134  adaptable method for building an arsenal of antibacterials potentially capable of targeting any path
135                                    Quinolone antibacterials represent one of medicine's most importan
136 roquinolones, a class of clinically relevant antibacterials requiring metal ions for efficient drug b
137 rapped on bacterial chromosomes by quinolone antibacterials, reversible complexes form that contain D
138 presence of folate analogs (methotrexate) or antibacterials (sulfonamines) does not affect our method
139                            The oxazolidinone antibacterials target the 50S subunit of prokaryotic rib
140  approach to this problem is to identify new antibacterials that act through validated drug targets s
141 al infections demands the development of new antibacterials that are not subject to existing mechanis
142 s a key step for the eventual development of antibacterials that block translocon assembly.
143                                              Antibacterials that disrupt cell membrane function have
144                             Bacteria produce antibacterials that drive competition and regulate commu
145 o reversible corruption by fluoroquinolones, antibacterials that form drug-enzyme-DNA complexes in wh
146 e increases sensitivity to fluoroquinolones; antibacterials that kill cells by inhibiting topoisomera
147 ty are not susceptible to the broad-spectrum antibacterials that most patients receive.
148     Such inhibitors may represent a class of antibacterials that potentially may represent a breakthr
149          Fluoroquinolones are broad-spectrum antibacterials that target DNA gyrase by stabilizing DNA
150  transport is vital for the discovery of new antibacterials; the finding that one amino acid change c
151  quinolones are the most commonly prescribed antibacterials, their use is threatened by an increasing
152 us success of beta-lactams as broad-spectrum antibacterials, they have never been widely used for the
153 t the threshold of regulatory innovation for antibacterials to treat drug-resistant infections, in wh
154 al information to guide selection of topical antibacterials used for empirical management of ocular i
155 ed in randomized controlled trials (RCTs) of antibacterials used to treat Staphylococcus aureus infec
156                            The trial design, antibacterials used, and end points studied were analyze
157 enable the design of novel anticoagulants or antibacterials using coumarin as a scaffold.
158 acycline and ampicillin, two clinically used antibacterials, was observed.
159 d to automatic European access, as 14 of the antibacterials were approved by the European Medicines A
160                                    Synthetic antibacterials were identified that inhibit the second e
161                                 Eighteen new antibacterials were identified.
162                                              Antibacterials were prescribed to 20 (11.5%) of 174 chil
163                              The most potent antibacterials were simple hydroxybutyl and methoxybutyl
164     This study tests this assumption for new antibacterials, which are saved as a last resort in orde
165 ide to eukaryotes is the capacity to produce antibacterials, which have evolved in prokaryotes as the
166                              Fluoroquinolone antibacterials, which target DNA gyrase, are critical ag
167 e potent, broad spectrum, ribosome-targeting antibacterials whose clinical efficacy is seriously thre
168  have discovered a promising class of potent antibacterials with a previously undescribed mechanism o
169  pathway resulted in the generation of novel antibacterials with in vitro potency comparable to that
170 ompounds such as 5, 16, 19, and 21) are good antibacterials with reduced or no activity, within the d
171 tions of compound functionality and revealed antibacterials with unconventional modes of action (MoAs
172 ssembled polymer nanoparticles are promising antibacterials, with nonspherical morphologies of partic
173 ged approach investigating the metabolism of antibacterials within both the host and bacterium is out
174 chniques to study the fate of small-molecule antibacterials within the targeted organism.

 
Page Top